| pubmed-article:7490806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0007138 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0042670 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0205281 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C0039260 | lld:lifeskim |
| pubmed-article:7490806 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:7490806 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7490806 | pubmed:dateCreated | 1996-1-4 | lld:pubmed |
| pubmed-article:7490806 | pubmed:abstractText | The feasibility of adjuvant cisplatin, methotrexate and vinblastine chemotherapy was evaluated in Taiwanese patients with invasive transitional cell carcinoma at high risk for recurrence. | lld:pubmed |
| pubmed-article:7490806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7490806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7490806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7490806 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7490806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7490806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7490806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7490806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7490806 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7490806 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:ChenK KKK | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:ChengP CPC | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:ChenP MPM | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:WeiC HCH | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:HsiehR KRK | lld:pubmed |
| pubmed-article:7490806 | pubmed:author | pubmed-author:ChiouT JTJ | lld:pubmed |
| pubmed-article:7490806 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7490806 | pubmed:volume | 155 | lld:pubmed |
| pubmed-article:7490806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7490806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7490806 | pubmed:pagination | 118-21 | lld:pubmed |
| pubmed-article:7490806 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:meshHeading | pubmed-meshheading:7490806-... | lld:pubmed |
| pubmed-article:7490806 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:7490806 | pubmed:articleTitle | Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. | lld:pubmed |
| pubmed-article:7490806 | pubmed:affiliation | Department of Medicine, Veterans General Hospital-Taipei, Taiwan, Republic of China. | lld:pubmed |
| pubmed-article:7490806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7490806 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7490806 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7490806 | lld:pubmed |
